Transgene SA (TNG.PA)
Paris · EUR · Healthcare · Biotechnology
€0.678 (-0.29%) as of
Key statistics
- Market cap
- 188.66M
- Forward P/E
- -3.08
- EPS (TTM)
- -0.1700
- Dividend yield
- 0.00%
- 52-week range
- 0.6700 – 1.5000
- Beta
- 0.72
- Revenue (TTM)
- 5.62M
- Profit margin
- 0.00%
- Analyst target
- €1.10
- Volume
- 16.31k
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Illkirch-Graffenstaden, France
- Employees
- 152
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.